Address
505 Coast Boulevard South
La Jolla, CA 92037
United States of America (the)
Phone
858-952-5500
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
June 14, 2023
| Name | Title | Pay | Year Born |
| A. Rachel Leheny | Chief Executive Officer & Director | 430,925 | 1963 |
| Eric W. Roberts | Chief Business Officer & Vice Chairman of the Board | 403,836 | 1964 |
| Sudarshan Hebbar | Chief Medical Officer | 430,828 | 1966 |
| Kenneth A. Stauderman | Co-Founder & Chief Scientific Officer | 615,594 | 1954 |
| John Dunn | General Counsel | 0 | 1952 |
| Michael J. Dunn | President & Chief Operating Officer | 0 | 1956 |
| Anjana Rao | Co-Founder and Scientific Advisor | 0 | N/A |
| Patrick Hogan | Co-Founder and Scientific Advisor | 0 | N/A |
| Stefan Feske | Co-Founder and Scientific Advisor | 0 | N/A |
| Stephen Bardin | Chief Financial Officer | 0 | 1991 |
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.